Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Eliminates Roadblock To Remicade Biosimilar Launch

Executive Summary

October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.

Advertisement

Related Content

Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Biosimilar Litigation: Janssen Vs. Samsung Anticipates Supreme Court Decision
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Pfizer's Remicade Biosimilar: Sept. 15 Is Earliest Launch Date

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS118983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel